Towards alpha-blockade–free surgery for pheochromocytoma and paraganglioma: experience from a newly established adrenal center
Year: 2026
Type: article
Study design: Observational Study
Abstract: INTRODUCTION: Pheochromocytomas are rare catecholamine-secreting tumors for which surgical resection is the definitive treatment. Traditionally, preoperative alpha-adrenergic blockade is strictly recommended. However, recent evidence has questioned its necessity. In this study, we report our experience with pheochromocytoma surgery at a newly established adrenal center without prior specialization in adrenal surgery. PATIENTS AND METHODS: From May 2022 to May 2026, 18 patients (14 female, 4 male; median age 63.1 years, interquartile range (IQR) 46.2-70.1) with catecholamine-producing tumors (15 pheochromocytomas and 3 paragangliomas) underwent surgical resection in our institution. Seventeen patients did not receive any preoperative alpha-adrenergic blockade, whereas one patient underwent surgery while already receiving phenoxybenzamine therapy initiated by the referral physician prior to admission. Intraoperative management included general anaesthesia, central venous access, and invasive arterial blood pressure monitoring. Urapidil and/or nitroglycerin were used as the primary antihypertensive agents. Data were prospectively collected and retrospectively analyzed, including patient demographics, preoperative metanephrine and normetanephrine secretion, intraoperative treatment of hypertension and hypotension, and postoperative outcomes. RESULTS: The median operative time was 49.5 min (IQR, 30-90). Sixteen procedures were performed minimally invasively (15 retroperitoneoscopic and one laparoscopic), and two by open approach. Partial adrenalectomy was performed in seven cases. Histology confirmed chromaffin cell tumors in all cases, with a median tumor size of 4.0 cm (IQR 3.15-5.15). Median peak intraoperative systolic blood pressure was 195 mmHg (IQR, 166-200). For intraoperative blood pressure control, urapidil was administered to 4 patients (22.2%), nitroglycerin to 3 (16.7%), and both agents to 3 (16.7%). The remaining 8 patients (44.4%), did not require pharmacological treatment. Ten patients (55.6%) had a maximum intraoperative noradrenaline requirement < 0.2 µg/kg/min, 5 (27.8%) required intermediate doses of 0.2-0.4 µg/kg/min, and 3 (16.7%) required high doses > 0.4 µg/kg/min. Median postoperative hospital stay was 2 days (IQR, 2-3). Two patients developed transient atrial fibrillation. No major complications or mortality occurred. CONCLUSION: Our results support the feasibility of alpha-blockade-free surgery for pheochromocytoma, even in centers with limited prior experience in pheochromocytoma surgery. Education of the anaesthesiology team, structured perioperative protocols, and close interdisciplinary collaboration appear to be important for ensuring safe perioperative management.
Source: Langenbeck s Archives of Surgery
Language: English
Subfield: Surgery
Field: Medicine
Domain: Health Sciences
Open Access status: hybrid
Estimated APC paid: $4,590
OpenAlex ID: W7234248034
